SGX-listed Singapore eDevelopment Ltd (“SeD”, SGX:40V) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic,…
SGX-listed Singapore eDevelopment Ltd (“SeD”, SGX:40V) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic,…
SINGAPORE – (ACN Newswire) – Singapore Exchange-listed Singapore eDevelopment Limited (“SeD”) announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. (“Global BioLife”),…